Comparative efficacy of cefotiam versus cephalothin in the therapy of skin and soft tissue infections.

Abstract

Cefotiam was evaluated by a comparative open-label randomized trial with cephalothin in the therapy of skin and soft tissue infections in 39 patients. The most common organism isolated was Staphylococcus aureus (78%). We established evidence of primary infection with gram-negative bacilli in four patients, three of whom were diabetic. Eight patients had mixed infections or superinfections. No patient was evaluated as a treatment failure; for 10 of 39 patients we were unable to recover an etiological agent but demonstrated a clinical cure. Cefotiam was found to be as effective as cephalothin in the therapy of skin and soft tissue infections.

• Authors: J R Lentino, M Stachowski, R Strikas, P Parrillo
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 25 Issue 6 Pg. 778-80 (Jun 1984) ISSN: 0066-4804 [Print] United States
• PMID: 6331302 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Cefotiam
• Cefotaxime
• Cephalothin

Topics

• Adult
• Aged
• Bacterial Infections (drug therapy, microbiology)
• Cefotaxime (adverse effects, analogs & derivatives, therapeutic use)
• Cefotiam
• Cellulitis (drug therapy)
• Cephalothin (adverse effects, therapeutic use)
• Drug Evaluation
• Humans
• Impetigo (drug therapy)
• Male
• Microbial Sensitivity Tests
• Middle Aged
• Random Allocation